Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Harry Rastedt was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. お知らせ • Apr 13
Abera Bioscience AB to Report Q1, 2026 Results on May 12, 2026 Abera Bioscience AB announced that they will report Q1, 2026 results on May 12, 2026 お知らせ • Jan 13
Abera Bioscience AB to Report Fiscal Year 2025 Results on Feb 12, 2026 Abera Bioscience AB announced that they will report fiscal year 2025 results on Feb 12, 2026 お知らせ • Oct 15
Abera Bioscience AB to Report Q3, 2025 Results on Nov 13, 2025 Abera Bioscience AB announced that they will report Q3, 2025 results on Nov 13, 2025 お知らせ • Jul 23
Abera Bioscience AB to Report Q2, 2025 Results on Aug 21, 2025 Abera Bioscience AB announced that they will report Q2, 2025 results on Aug 21, 2025 お知らせ • Apr 14
Abera Bioscience AB to Report Q1, 2025 Results on May 13, 2025 Abera Bioscience AB announced that they will report Q1, 2025 results on May 13, 2025 お知らせ • Apr 10
Orexo Announces Positive In-Vivo Proof-Of-Concept Data for Powder-Based Intranasal Vaccine Formulated with the Amorphox Technology Orexo AB (publ.) announced positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between Orexo and Abera Biosciences ("Abera") entered in December 2024. The proof-of-concept study was conducted in rats where Abera's influenza vaccine candidate was administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology. Both formulations induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA). No difference in immune response was seen between the liquid nasal solution and the intranasal powder. An intranasal influenza vaccine has the potential to easily and effectively help reduce the spread of infections and prevent disease, which could play an important role in a potential future pandemic. Formulating vaccines in powder form using the AmorphOX technology provides the potential to develop cost-efficient, thermostable vaccines with no need for cold chain requirements. お知らせ • Jan 15
Abera Bioscience AB to Report Fiscal Year 2024 Results on Feb 13, 2025 Abera Bioscience AB announced that they will report fiscal year 2024 results on Feb 13, 2025 お知らせ • Oct 15
Abera Bioscience AB to Report Q3, 2024 Results on Nov 13, 2024 Abera Bioscience AB announced that they will report Q3, 2024 results on Nov 13, 2024 お知らせ • Jul 23
Abera Bioscience AB to Report Q2, 2024 Results on Aug 21, 2024 Abera Bioscience AB announced that they will report Q2, 2024 results on Aug 21, 2024 お知らせ • Apr 16
Abera Bioscience AB to Report Q1, 2024 Results on May 14, 2024 Abera Bioscience AB announced that they will report Q1, 2024 results on May 14, 2024 お知らせ • Jan 24
Abera Bioscience AB to Report Fiscal Year 2023 Results on Feb 22, 2024 Abera Bioscience AB announced that they will report fiscal year 2023 results on Feb 22, 2024 お知らせ • Oct 16
Abera Bioscience AB to Report Q3, 2023 Results on Nov 14, 2023 Abera Bioscience AB announced that they will report Q3, 2023 results on Nov 14, 2023 Board Change • Sep 20
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Aug 21
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. お知らせ • Jul 18
Abera Bioscience AB to Report Q2, 2023 Results on Aug 16, 2023 Abera Bioscience AB announced that they will report Q2, 2023 results on Aug 16, 2023 Board Change • Feb 23
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Feb 02
No independent directors There are 7 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. お知らせ • Jan 25
Abera Bioscience AB to Report Fiscal Year 2022 Results on Feb 23, 2023 Abera Bioscience AB announced that they will report fiscal year 2022 results on Feb 23, 2023 Board Change • Nov 21
No independent directors There are 6 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 6 new directors. 3 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Executive Chairman of Board Anders Ericsson is the most experienced director on the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. お知らせ • May 17
Abera Bioscience AB, Annual General Meeting, Jun 14, 2022 Abera Bioscience AB, Annual General Meeting, Jun 14, 2022. Board Change • Apr 28
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Member of the Advisory Board Camille Locht was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.